“ Eligible patients were women 18 years of age with early stage histologically or cytologically confirmed breast cancer who had hormone receptor positive cancer ie, estrogen receptor positive or progesterone receptor positive, who were undergoing adjuvant aromatase inhibitor therapy, and who had completed their treatment pathway surgery, chemotherapy, radiation, and or hormone therapy 4 weeks before study entry kob lasix ”